Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 8;12:145-150.
doi: 10.2147/CMAR.S229022. eCollection 2020.

Expression and Prognostic Significance of BANF1 in Triple-Negative Breast Cancer

Affiliations
Free PMC article

Expression and Prognostic Significance of BANF1 in Triple-Negative Breast Cancer

Genhao Zhang. Cancer Manag Res. .
Free PMC article

Abstract

Aim: To investigate the expression of barrier-to-autointegration factor 1 (BANF1) and its prognostic significance in triple-negative breast cancer (TNBC).

Methods: BANF1 immunohistochemical detection was performed in 60 TNBC specimens and 30 normal control tissues. Real-time PCR was performed to assess the expression of BANF1 gene in TNBC tissues and their correlations with proliferation and metastasis. Kaplan-Meier survival analysis was used to assess the effect of BANF1 expression on the relapse-free survival (RFS) of TNBC patients. Univariable and multivariable Cox proportional hazards regression model analysis was used to confirm independent prognostic factors.

Results: Expression of BANF1 in TNBC was significantly higher than that of the normal control group (p<0.001), and it was related to the status of lymph node metastasis and TNM staging (p<0.05), and not related to age and tumor size (p>0.05). BANF1 expression has a positive correlation with MKI67 and MTA1 expression (p<0.01). Univariable analysis showed that expression of BANF1, the status of lymph node metastasis and TNM stage were related to the relapse-free survival (RSF) of TNBC patients (p<0.001, p=0.001, p=0.013, respectively). Multivariable Cox regression indicated that the status of lymph node metastasis was an independent prognostic factor for TNBC patients (p<0.001). The survival curve suggested that the survival times for TNBC patients with high BANF1 expression have no difference compared with that for the low-expression patients (p>0.05).

Conclusion: Expression of BANF1 may play a role in the occurrence and development of TNBC. Lymph node metastasis was the only independent prognostic factor predicts a poor prognosis.

Keywords: BANF1; prognosis; relapse-free survival.

Conflict of interest statement

The author reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Expression of BANF1 protein in TNBC tissues. (A) Low expression. (B) High expression. EnVision ×200.
Figure 2
Figure 2
Expression of BANF1 in TNBC and their correlations with proliferation and metastasis. (A) BANF1 gene is overexpressed in TNBC (*p <0.05). (B, C) BANF1 expression has a positive correlation with MIK67 and MTA1 expression (p <0.01).
Figure 3
Figure 3
Relationship between BANF1 expression and TNBC relapse-free survival (RFS). (A) Survival analysis was carried out with our patient dataset, n=56. (B) Survival analysis was carried out with publicly available datasets using KM Plotter, n=256.

Similar articles

See all similar articles

References

    1. Nakhjavani M, Palethorpe HM, Tomita Y, et al. Stereoselective anti-cancer activities of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals (Basel). 2019;12(3). doi:10.3390/ph12030117 - DOI - PMC - PubMed
    1. Mazumdar A, Tahaney WM, Reddy Bollu L, et al. The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. NPJ Breast Cancer. 2019;5:22. doi:10.1038/s41523-019-0118-6 - DOI - PMC - PubMed
    1. Dharmaraj T, Guan Y, Liu J, Badens C, Gaborit B, Wilson KL. Rare BANF1 alleles and relatively frequent EMD alleles including ‘healthy lipid’ emerin p.D149H in the ExAC cohort. Front Cell Dev Biol. 2019;7:48. doi:10.3389/fcell.2019.00048 - DOI - PMC - PubMed
    1. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-9 - DOI - PubMed
    1. Srinivasalu VK, Susan A, Jose WM, Philip A, Nambiar A, Pavithran K. 41P prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC). Ann Oncol. 2019;30(Supplement_3):mdz095–040
Feedback